Clinical Trial Update: Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma [Phase 2]

View source ↗

Summary

Phase II trial update for MEDI4736 (durvalumab) in combination with chemotherapy as first-line treatment for unresectable mesothelioma; study completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesothelioma
• Pleural Mesothelioma

Drugs mentioned

• MEDI4736 (Durvalumab)

Snippet

Sponsor: PrECOG, LLC. | Conditions: Mesothelioma, Pleural Mesothelioma | Phase 2 | Status: COMPLETED | Results posted: 2021-04-06